Entrepreneurship

e-NIOS Applications

e-NIOS Applications S.A. (e-Noesis Inspired Operational Systems) is a NHRF spin-off company specialized in Bioinformatics, founded by the members of the Metabolic Engineering and Bioinformatics Group, Drs Aristotle Chatziioannou (Research Director), Eleftherios Pilalis and Ioannis Valavanis (post-doctoral researchers). e-NIOS has received VC funding from the European Investment Fund through PJ Tech Catalyst Fund and the Incubator of InfoQuest Holdings Iqbility. The company targets data-driven, signature-aided interpretation of -omics data, using Big Data computing methodologies ported in Cloud infrastructures, represents one of the first examples internationally of digital Biotech companies, having recently concluded on a strategic partnership with a pioneering company from the Boston ecosystem, Seven Bridges, a world leader in Cloud Solution for Biomedical Big Data Computing, for the development of disruptive solutions regarding data-driven, automated interpretation of bulky genomic data. The expertise of the e-NIOS team is inherently multidisciplinary, encompassing extensive research experience in the fields of Bioinformatics, Genomics, Artificial Intelligence, Data Mining, Operational Research and Decision Support Systems.s. A. Chatziioannou and E. Pilalis are currently serving as Chief Executive Officer (CEO) and Chief Technology Officer (CTO) of e-NIOS, respectively.

e-NIOS was selected by the Hellenic Development Bank (HDB) as model company of Technological Innovation for Greece, thus allowing the company to become a member of the HDB Innoagora acceleration platform (9/2021)

ResQ Biotech

ResQ Biotech Private Company (Patras, Greece). ResQ Biotech is a spin-off company of the Institute of Chemical Biology of the National Hellenic Research Foundation founded in 6/2019 at the Patras Science Park by Dr. Georgios Skretas (Research Director, ICB-NHRF) and Dr Dafni Delivoria (Post-doctoral research associate, ICB-NHRF) and Mrs. Athina Oikonomidou (resqbiotech.com). It is a platform technology/Drug discovery company targeting diseases caused by problematic protein folding and aggregation (Alzheimer’s disease, amyotrophic lateral sclerosis, cancer, systemic amyloidosis etc.). Its proprietary biotechnological approach uses genetically engineered E. coli bacteria to biosynthesize billions of cyclic oligopeptides, an emerging class of therapeutic molecules, and simultaneously screen them to identify inhibitors of pathogenic protein misfolding and aggregation. ResQ Biotech aspires to become a partner of choice for every Pharma & Biotech company that is developing Drugs for protein misfolding diseases and looking for new assets to expand their pipelines. Since December 2019, ResQ Biotech has been member of the Hellenic Bio-cluster (www.hbio.gr) and since July 2021 member of the national startup registry “Elevate Greece”.

• ResQ Biotech has been selected by Nature as one of the most-exciting science-based companies to have emerged from academic institutions in the past few years as part of the 2020 Spinoff Prize.
• ResQ Biotech was the winner of the 2023 MIT Global Startup Workshop pitch competition.
• ResQ Biotech was the winner of the MIT Enterprise Forum Greece Startup Competition 2020.
• ResQ Biotech has been selected by the editors of Startupper magazine among the 100 companies with the ability to change the business landscape of Greece characterized as «Game Changers» of the year in 2020.
• ResQ Biotech has secured >1,000,000 euros in private and public funding for the pre-clinical development of its leading indications.

ACE (Advanced Cure Electronics)

ACE (Advanced Cure Electronics) (Athens, Greece). Established in 6/2019 as a spin-off company of the NHRF to pursue pre-clinical development and commercial exploitation of new conjugated polymers as contrast agents for optical imaging modalities (photoacoustic and fluorescence) and therapy (Drugs or photodynamic and photothermal) discovered at the ICB. C. Chochos is a co-founder of the company.

QuadrEL

QuadrEL.Srl (Modena, Italy), a start-up company established in 5/2020 with the aim of research, development, production and marketing in the field of pharmaceutical products, veterinary Drugs, innovative Drugs and biotechnologies. QuadrEL focuses mainly on infectious diseases. ICB Research Director Dr.. T. Calogeropoulou is a co-founder of the company. The company was acquired by the multinational company Fatro SA on 10/2022, and is currently developing a drug for canine leishmaniasis.